Omega Pharma Innovation & Development SA
38.2 FTEOmega Pharma Innovation & Development reported revenue of €16.3m for the 2025 financial year (annual accounts filed with the NBB on 07 Jul 2026), with 38.2 full-time equivalents.
The score of Omega Pharma Innovation & Development shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Revenue -67 % Equity +95 % Total assets +69 % Headcount (avg FTE) -14 %
Accounts of the company itself (not consolidated).
The full file covers 9 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Omega Pharma Innovation & Development's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | €16.3m | ||||
| Net result | €11.4m | ||||
| Equity | €240.2m | ||||
| Cash | 7,220 € | ||||
| EBITDA | 997,003 € | ||||
| Total assets | €246.6m |
Filed annual accounts
- Year ended 31 Dec 2025filed on 07 Jul 2026
- Year ended 31 Dec 2024filed on 18 Jun 2025
- Year ended 31 Dec 2023filed on 22 May 2024
- Year ended 31 Dec 2022filed on 25 May 2023
- Year ended 31 Dec 2021filed on 17 Jun 2022
Omega Pharma Innovation & Development's financial analysis
- Solvency97.4%sector median: 60.4%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Omega Pharma Innovation & Development
4 active director(s) in the register.
Omega Pharma Innovation & Development's shareholders and holdings →Omega Pharma Innovation & Development's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0884.084.724
- VAT number
- BE0884084724
- Peppol
- Registered · 0208:0884084724 · as of 10 Nov 2026
- Legal form
- SA
- Incorporated
- 09 Oct 2006
- Registered office
- 9050 Ghent
- Size
- Small · 38.2 FTE
- Latest accounts
- 2025 · filed on 07 Jul 2026
- Activity
- Research and experimental development on biotechnology (NACE 72101)
Omega Pharma Innovation & Development (SA) has been based in Ghent since 2006, active in: research and experimental development on biotechnology. For 2025, it reports revenue of €16.3m, a net profit of €11.4m and equity of €240.2m. With 38.2 full-time equivalents, it is a small enterprise by headcount. Its solvency stands at 97.4%, above the median of its sector (60.4%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Omega Pharma Innovation & Development
Companies in the same business, of comparable size and area, outside its group.
- Ablynx Research and experimental development on natural sciences and engineering Ghent · balance sheet €417.3m
- Kaneka Eurogentec Manufacture of pharmaceutical preparations Seraing · balance sheet €115.4m
- Lakefront Biotherapeutics Research and experimental development on natural sciences and engineering Mechelen · balance sheet €3.34bn
- Ardena Holding Research and experimental development on natural sciences and engineering Ghent · balance sheet €87.1m
- Cellistic Manufacture of pharmaceutical preparations Mont-Saint-Guibert · balance sheet €41.6m
- ViiV Healthcare Research and experimental development on natural sciences and engineering Wavre · balance sheet €17.0m
- UCB Developed Brands Research and experimental development on natural sciences and engineering Anderlecht · balance sheet €1.07bn
- Laboratoires S.M.B. Manufacture of pharmaceutical preparations Molenbeek-Saint-Jean · balance sheet €261.5m
Frequently asked questions about Omega Pharma Innovation & Development
What is the revenue of Omega Pharma Innovation & Development?
According to the 2025 annual accounts filed with the NBB, the revenue of Omega Pharma Innovation & Development amounts to 16,348,779 €.
What is the VAT number of Omega Pharma Innovation & Development?
In Belgium, the VAT number is the company number prefixed with BE: BE0884084724 for Omega Pharma Innovation & Development, if the company is VAT-registered. Its company number (CBE) is 0884.084.724.
Where is the registered office of Omega Pharma Innovation & Development?
According to the CBE register, the registered office of Omega Pharma Innovation & Development is in 9050 Ghent.
What is the equity of Omega Pharma Innovation & Development?
At the close of the 2025 financial year, the equity of Omega Pharma Innovation & Development amounts to 240,227,970 €, a solvency of 97.4% of total assets.
How many people work at Omega Pharma Innovation & Development?
38.2 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Omega Pharma Innovation & Development?
The register lists 4 active mandates at Omega Pharma Innovation & Development. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Omega Pharma Innovation & Development
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →